

Quarter 1 2026-27: Results and Forecast Report

13 August 2026




Quarter 1 performance at a glance



National medicine licence applications delivered on time



Vaccines and blood products certified on time



Customer satisfaction with scientific advice (30 day target)



Median time to provide written scientific advice (30 day target)



New manufacturing licences (90 day target)




Median vaccine batch testing time (43 day target)

11,323



Customer enquiries handled



FOI requests responded to on time

Confidence in performance



Clinical trials and investigations
assessed on time



Recognition of international medicines licences
determined on time



Adverse incidents
processed within 24 hours



Vaccines and blood products
certified on time



National variations
determined on time




Scientific advice requests written advice
delivered on time



National medicines licence applications
determined on time



Decisions on manufacturing and distribution authorisations
made on time



Timely decisions on clinical trials and investigations



Median time target (days)



Median time Q1 (days)



Minimum time Q1 (days)



Maximum time Q1 (days)

Clinical trial
authorisations

Initials

30

29

1

70

Modifications

35

35

1

52

Clinical
investigations

Initials

60

58

52

60

Modifications

21

6

0

38

Quality scientific advice



Reliable licensing timelines



**Median time
target (days)**

210

210

60

110



**Median time
Q1 (days)**

196

162

57

104



**Minimum time
Q1 (days)**

50

157

47

38



**Maximum time
Q1 (days)**

210

167

60

111

National
marketing
authorisations
granted

Established
medicines

New active
substances

IRP marketing
authorisations
granted

Route A

Route B

Robust variations timelines



**Median time
target (days)**



**Median time
Q1 (days)**



**Minimum time
Q1 (days)**



**Maximum time
Q1 (days)**

Measure

Type Ib – National

30

15

0

119

Type Ib – Safety

30

15

0

35

Type II – National

90

56

0

122

Type II – Safety

90

56


0

248

Consistent timelines for wholesale dealer and manufacturing licences

			
		Median time target (days)	Median time Q1 (days)
Wholesale Dealer Licences	New application	90	50
	Variation: Inspection	90	38
	Variation: No inspection	30	15
Manufacturing Licences	New application	90	34
	Variation: Inspection	90	43
	Variation: No inspection	30	13

Responsive batch control testing delivery

		 Median time target (days)	 Median time Q1 (days)	 Minimum time Q1 (days)	 Maximum time Q1 (days)
Batch Control Testing	Blood products	15	5	0	22
	Vaccines	43	3	0	30

Transparent and timely responses

Category	 Parliamentary questions	 Customer enquiries	 Complaints	 FOI requests
Volume	92	11,323	5	278
Q1 Responded on time	95%	93%	100%	97%
Target for on-time responses	85%	90%	90%	90%

Forecast for next quarter



Publish
MHRA2030
Strategy



Welcome
recommendations
of the National
Commission into
the Regulation of
AI in Healthcare



Consult on future of
MHRA fees



Advance innovative
access and licensing
pathways



Showcase priorities
at the MHRA-DIA
Global Annual
Summit

Thank you

© Crown copyright 2026

Produced by the Medicines and Healthcare products Regulatory Agency

You may re-use this information (excluding logos) with the permission from the Medicines and Healthcare products Regulatory Agency, under a Delegation of Authority. To view the guideline, visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information> or email: copyright@mhra.gov.uk.

Where we have identified any third-party copyright material you will need to obtain permission from the copyright holders concerned.

The names, images and logos identifying the Medicines and Healthcare products Regulatory Agency are proprietary marks. All the agency logos are registered Trademarks and cannot be used without the MHRA's explicit permission.

